The present invention relates to the use of terguride and proterguride for the prophylaxis and/or the treatment of chronic pain conditions as well as to pharmaceutical com positions comprising terguride and/or proterguride option ally together with an opiate analgesic.
0004 If a pain event lasts for more than three to six months, it is referred to as chronic pain. Causes thereof may be incurable diseases such as malignant tumors or rheumatic diseases. However, the connection between the pain and the disorder or respectively the disease which originally caused the pain is often no longer identifiable or the original disorder can no longer be remedied. Furthermore, various environmental influences like stress or weather changes can trigger or enhance the pain. A chronic pain presentation often includes different forms of pain. 0005 Back pains (amongst others as a consequence of herniated discs, nerve root compression syndrome), head pains (amongst others migraine, tension-type headache, cluster headache), rheumatic pains (amongst others arthritis, fibromyalgia), neuralgias (amongst others trigeminal neu ralgia, herpes Zoster), tumor associated pains (amongst others brain tumor, bone metastases), degenerative pains (amongst others osteoporosis, arthrosis) and phantom pains (amongst others after amputation, plexus lesion) are men tioned as the most frequent forms of chronic pain. 0006 Chronic pains often last for several years or decades. Frequently, patients Suffering from chronic pain develop emotional problems. Many pain patients suffer from inactivity and listlessness; they are hopeless and desperate, complain about feelings of anxiety and depression, perceive themselves as limited in their self-esteem. Such psychic symptoms are warning signs of a chronification, just as general, nonspecific physical complaints such as intestine associated problems (diarrhea or respectively constipation), irritable bladder, dizziness, dyspnea, palpitations or a feeling of tightness in the chest. 0007 Different mechanisms in the peripheral and central nervous systems are involved in the causation of chronic pain. The sensitization of pain fibers and their local hyper excitability are Substantial pathogenic mechanisms which are relevant as far as peripheral pain perception in the course of the causation of chronic pain conditions is concerned.
Other pathomechanisms comprise the longer lasting enhancement of pain signals and a recruitment of usually silent nerve fibers in the area of the spinal cord that lead to a larger spatial extension of the pain perception. Finally, in the brain the pain potentials arriving in increased number from the periphery lead to changes in the signal transmission Sep. 27, 2007 in terms of an enhancement of the pain perception and a long-term change in pain processing. 0008 Even when lasting only for a few minutes, inten sive pain stimuli can lead to persistent structural and func tional changes which intensify the transmission and the processing of pain stimuli. These procedures are similar to cellular activities such as those that can be observed in all more complex, neuronal learning processes; consequently, it is analogously referred to as pain memory. In said context, the term pain memory includes the ability of the nervous system to generate a memory trace for an occurred painful stimulation through the whole pain processing system. 0009. In this context, certain nuclei in the brain have a key function in pain processing. 0014. This object is solved by the technical teaching of the independent claims. Other advantageous embodiments, aspects and details of the invention result from the depen dent claims, the description and the examples. 0015 The present invention discloses the use of terguride or proterguride or a combination of both for the manufacture of drugs for the prophylaxis and the treatment of chronic pain and chronic pain conditions. Fatigue Syndrome and leads to a severe performance reduc tion compared to the habitual former performance, a fact that prevents the patient from leading a normal live. 0020. Furthermore, terguride and proterguride as well as combinations of both are very well suited for the prophy laxis and the treatment of head pains and migraine. Tergu ride or proterguride used in Small doses in a prophylactic manner or in case of the first signs of head pains and migraine relieve these discomforts considerably and in some cases within Some hours.
0021. Furthermore, the substances terguride and proter guride are very well suited for the prophylaxis and the treatment of pains associated with premenstrual syndrome, mastalgia, of stomach pains associated with the irritable colon as well as pains associated with carcinoid syndrome. Also, degenerative pains, osteoporosis, arthrosis as well as phantom pains for example after amputation or plexus lesion are other types of pain which can be treated with terguride and/or proterguride. According to the invention, the two active agents can also be used for addressing pains or respectively pain conditions associated with neuralgias, trigeminal neuralgia, herpes Zoster, postherpetic neuralgias as well as neuropathic pains and tumor associated pains. The tumor associated pains are particularly caused by brain tumors or bone metastases.
0022. Another aspect of the present invention concerns a combination of terguride or proterguride or of terguride and proterguride with an opiate analgesic as well as to the use of this combination for the prophylaxis and the treatment of the indications mentioned herein.
0023. It has been shown that a combination of terguride and at least one opiate analgesic or a combination of proterguride and at least one opiate analgesic or a combi nation of terguride and proterguride and at least one opiate analgesic is more efficient than the respective single com ponents, with the undesired side effects of the at least one Sep. 27, 2007 opiate analgesic being reduced or the activity of the at least one opiate analgesic being increased. 0024. The following compounds can be particularly men tioned as opiate analgesics: dihydrocodeine, tramadol, mor phine, morphine Sulfate, oxycodone, methadone, hydromor phone, buprenorphine as well as fentanyl. 0025. The applications according to the invention are Suitable for a continuous application since no physical or psychic addiction has occurred and also in case of admin istration over several months, no loss of efficacy has been observed. Moreover, it could also be shown that both terguride and proterguride could be used with a comparable efficacy when the presentation was recurrent, even in cases where it was discontinued once the pain presentation had subsided.
0026. The substances according to the invention are characterized by a broad spectrum of activity as far as the dopaminergic, serotoninergic and the noradrenergic neu rotransmitter systems are concerned. In the active agents, one single molecule combines different active principles which are relevant for different central nervous pain trans mission systems. It is Supposed that precisely this combi nation of characteristics in the Substances according to the invention is of crucial importance for the high therapeutic efficacy. Simultaneously, this combination has a positive effect on the mood, the cognitive performances and the daily activities of patients. A Surprising, positive effect on the overall condition of patients, an improvement of the sleep quality as well as the good tolerance of the active agents are advantageous for the good compliance of patients and contribute considerably to the Success of the therapy using the active agents according to the invention. 0027. Another aspect of the present invention relates to pharmaceutical compositions containing at least one phar macologically acceptable carrier, auxiliary agent and/or sol vent in addition to terguride or proterguride or a combination of terguride and proterguride or respectively their pharma cologically acceptable salts. 0028. Furthermore, it is preferred that the pharmaceutical composition further comprise at least one opiate analgesic. Together with terguride and/or proterguride, this at least one opiate analgesic can be contained in one single galenic formulation or it can be present as a second galenic formu lation which can be applied independently of the formula tion containing terguride and/or proterguride. Furthermore, the presence of two formulations in the pharmaceutical compositions is preferred since thus a certain concentration of terguride and/or proterguride regarding the opiate anal gesic can be better adjusted or respectively changed or the opiate analgesic can be entirely discontinued. 0029. These pharmaceutical compositions preferably contain terguride in the dose range of 0.1-3.0 mg per pharmaceutical formulation or proterguride in the dose range of 0.002-0.5 mg per pharmaceutical formulation. If the pharmaceutical formulation contains both terguride and pro terguride, the dose ranges from 0.1-3.0 mg for terguride and from 0.002-0.5 mg for proterguride are preferred. Sep. 27, 2007 0042. The patient complained about chronic pain in the extremities as well as about stomach pains and continuous exhaustion and tiredness. The discomforts had persisted for several months. No pretreatment had been realized prior to the treatment with terguride. 0043. The patient was treated with a daily dose of 3 mg of terguride which was administered in the morning and in the evening in single doses of 1.5 mg. The treatment was realized gradually. Over a period of 2 weeks, the daily dose of initially 0.25 mg was progressively increased to 3 mg. 0044) The treatment was realized over a period of 25 weeks and the condition of the patient was examined weekly. After just 10 weeks, the condition had visibly improved, in particular regarding the pains in the extremities and the stomach pains recorded by means of a visual analog scale.
0045. After 17 weeks, it was also nearly impossible to detect the chronic conditions of tiredness and exhaustion and according to the patient her normal performance, just as before the onset of the disease, was re-established.
Example 2 Application of Proterguride in the Case of Fibro myalgia 0046 A 29 year-old female patient suffering from fibro myalgia was treated with proterguride. 0047. The patient complained about stomach problems, stomach pains, pains in the chest as well as about Swollen breasts and continuous exhaustion and tiredness. The dis comforts had persisted for approx. one year. No pretreatment had been realized prior to the treatment with proterguride. 0048. The patient was treated with a daily dose of 0.5 mg of proterguride which was administered in the morning and in the evening. The treatment was realized gradually. Over a period of 2 weeks, the daily dose of initially 0.05 mg was progressively increased to 0.5 mg. 0049. The treatment was realized over a period of 33 weeks and the condition of the patient was examined weekly. After just 12 weeks, the condition had improved, particularly regarding the pains in the chest. Furthermore, a reduction of the swelling could be observed. 0050. After 20 weeks, also the chronic conditions of tiredness and exhaustion as well as the stomach pains had largely disappeared and after 30 weeks, the patient was in the same condition as before the onset of the disease.
Example 3 Application of Terguride in the Case of Mastalgia/ Premenstrual Syndrome 0051. A 34 year-old patient suffering from mastalgia and stomach pains due to premenstrual syndrome was treated with terguride. Laboratory analyses showed that the wom an's blood levels of prolactin were in the normal range. The therapy started in the middle of the cycle. Twice a day, a tablet containing 0.5 mg terguride was administered to the patient over a period of 3 months. The pain severity was observed by means of a visual analogue scale. During the therapy, the pains in the chest and stomach area decreased and the patient was able to renounce on the administration of additional pain medication. Furthermore, the patient reported a considerably improved general condition and joy dose of terguride was gradually reduced in the frame of a treatment-free interval wherein the pain increased quickly.
Example 7
Tumor Associated Pain 0057. A 62 year old tumor patient suffering from a pancreatic carcinoma complained about bone pains resulting from the development of bone metastases. The patient was treated with ibandronate. Additionally, the treatment was realized with ibuprofen, acetaminophen and desipramine. At short term, the treatment resulted in a pain relief which, however, decreased considerably within some weeks. After the start of the therapy with terguride (0.5 mg bid) the patient's pain conditions were reduced and the well-being improved continuously. No side effects were observed.
Example 8
Herniated Disc 0.058 Since two years, the patient (43 years) has been suffering from a herniated disc in the lower lumbar area (L5-S1) with extension to L4-L5. The chronic pain was treated with oxycodone of an initial dosage of 2x10 mg and the dose was increased to 2x40 mg per day. The pain intensity was considerably reduced under therapy. The longer the treatment lasted, the more complaints occurred due to constipation, finally requiring a dose reduction of oxycodone to 2x20 mg/day. This was related to an increase of the subjective pain intensity of the patient. Under co therapy with terguride (2x0.5 mg/day) the patient was almost completely pain-free; also, the constipation symp toms had disappeared completely. Under chronic therapy, the therapy with terguride remained efficient.
Example 9 Migraine Prophylaxis 0059. The 47 year-old patient suffered from migrainous headaches with an average of 4-5 attacks per month, lasting on average between 3 and 8 hours. For acute pain treatment during an attack, a dosage of 50 mg of Sumatriptan was administered orally. For the purpose of migraine prophy laxis, the patient was treated with topiramate in a dosage of 200 mg per day. No reduction of the migraine activity was observed under medication. After 3 months, the medication was discontinued due to nausea and weight loss. 0060 Under administration of terguride (2x0.25 mg per day), the number of pain attacks decreased considerably to only one pain attack within 6 weeks with low pain intensity; also, the well-being of the patient improved within 2 weeks after the start of the therapy. No side effects were observed.
In the frame of a treatment-free interval, the treatment with terguride was discontinued, whereupon the migraine pre sentation returned.
1. Use of terguride or proterguride or a combination of terguride and proterguride or pharmacologically acceptable salts thereof for the preparation of a drug for the prophylaxis and/or the treatment of chronic pain or chronic pain condi tions.
